KLHL12: A Potential Drug Target Or Biomarker (G59349)

Target Name: KLHL12

NCBI ID: G59349

KLHL12

KLHL12: A Potential Drug Target Or Biomarker

KLHL12, also known as Kelch-like protein C3IP1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the KLHL1 family of proteins, which are characterized by the presence of a variable region of the protein that contains a nucleotide-binding oligomerization domain (NBD) and a carboxy-terminal region (CTR).

The KLHL12 protein is of particular interest as a potential drug target or biomarker due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant functions of KLHL12 is its role in the regulation of cell division and apoptosis. KLHL12 has been shown to play a role in the regulation of mitosis, particularly in the G1/G2 phase of the cell cycle. In addition, KLHL12 has been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.

KLHL12 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

In addition to its role in cell division and apoptosis, KLHL12 has also been shown to be involved in the regulation of inflammation and immune responses. This is particularly relevant given that KLHL12 is expressed in a variety of tissues and has been implicated in the development of autoimmune disorders.

KLHL12 has also been shown to play a role in the regulation of cytoskeletal organization and dynamics. This is important for the proper functioning of cells and is particularly relevant given that KLHL12 is involved in the regulation of cell migration and the assembly of tissues.

Given the involvement of KLHL12 in so many cellular processes, it is of particular interest as a potential drug target or biomarker. Studies have shown that inhibiting KLHL12 can have a variety of therapeutic effects, including the inhibition of cancer cell growth, the regulation of neurodegenerative diseases, and the regulation of autoimmune disorders.

In addition to its potential therapeutic applications, KLHL12 is also of interest as a potential biomarker for a variety of diseases. For example, KLHL12 has been shown to be involved in the regulation of cancer cell proliferation, which could make it an attractive biomarker for the detection and treatment of cancer.

In addition, KLHL12 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This makes it an attractive candidate for use as a biomarker or drug target in these conditions.

Finally, KLHL12 has also been shown to be involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. This makes it an attractive candidate for use as a biomarker or drug target in these conditions.

In conclusion, KLHL12 is a protein that is of great interest due to its involvement in several cellular processes that are associated with various diseases. Its potential therapeutic applications as a drug target or biomarker make it an attractive candidate for further study. Further research is needed to fully understand the role of KLHL12 in cellular processes and its potential as a therapeutic agent.

Protein Name: Kelch Like Family Member 12

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a negative regulator of Wnt signaling pathway and ER-Golgi transport (PubMed:22358839, PubMed:27565346). The BCR(KLHL12) complex is involved in ER-Golgi transport by regulating the size of COPII coats, thereby playing a key role in collagen export, which is required for embryonic stem (ES) cells division: BCR(KLHL12) acts by mediating monoubiquitination of SEC31 (SEC31A or SEC31B) (PubMed:22358839, PubMed:27565346). The BCR(KLHL12) complex is also involved in neural crest specification: in response to cytosolic calcium increase, interacts with the heterodimer formed with PEF1 and PDCD6/ALG-2, leading to bridge together the BCR(KLHL12) complex and SEC31 (SEC31A or SEC31B), promoting monoubiquitination of SEC31 and subsequent collagen export (PubMed:27716508). As part of the BCR(KLHL12) complex, also acts as a negative regulator of the Wnt signaling pathway by mediating ubiquitination and subsequent proteolysis of DVL3 (PubMed:16547521). The BCR(KLHL12) complex also mediates polyubiquitination of DRD4 and PEF1, without leading to degradation of these proteins (PubMed:18303015, PubMed:20100572, PubMed:27716508)

The "KLHL12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets